Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Companies / Belgium

Industry Consolidation To Bring Long-Term Benefits

October 2006 | Company News Alert

Continuing the consolidation trend in the European pharmaceutical sector, Belgian firm UCB has unveiled a EUR4.4bn (US$5.6bn) bid for German company Schwarz Pharma to create major biopharmaceutical player specialising in neurology, inflammation and oncology.

Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.

[
: *
[
: *


If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.

If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.

Western Europe InsightWestern Europe Channels Western Europe Countries